Evidence map›Paper›PMID 41278167›Full record

Trial reportWorld journal of gastroenterology2025

Precision therapy guided by genotypic antibiotic resistance for

Yan Xu, Jing-Wen Hao, Cong-Cong Min, Lin Yang, Cui-Ping Ma, Chao Shi, Tao Mao, Zi-Bin Tian, Tong Wang, Ya-Nan Yu

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Association of Resistance-AssociatedAntibiotics (Basel, Switzerland) · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yan XuDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China.
Jing-Wen HaoDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China.
Cong-Cong MinDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China.
Lin YangDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China.
Cui-Ping MaCollege of Chemistry and Molecular Engineering, College of Biological Engineering, Qingdao Key Laboratory of Rapid Nucleic Acid Detection, Qingdao University of Science and Technology, Qingdao 266042, Shandong Province, China.
Chao ShiQingdao Nucleic Acid Rapid Testing International Science and Technology Cooperation Base, College of Life Sciences, Qingdao University, Qingdao 266071, Shandong Province, China.
Tao MaoDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China.
Zi-Bin TianDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China.
Tong WangDepartment of Epidemiology and Health Statistics, Qingdao University, Qingdao 266071, Shandong Province, China.
Ya-Nan YuDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China. yananyu@qdu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

aimTo investigate the efficacy of precision-guided first-line therapy for

methodsThis single-center randomized controlled trial enrolled 194

resultsOf 194 patients enrolled, 180 (92.8%) completed the study as planned. In the ITT analysis, the eradication rate was higher in the G-AST group than in the BQT group [92.8% (95%CI: 85.8-96.5)

conclusionG-AST-guided therapy yielded higher eradication rates than empirical BQT in first-line

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialHelicobacter InfectionsHelicobacter pyloriPrecision MedicineAdultAgedAmoxicillinBismuthChinaClarithromycinDrug Therapy, CombinationEsomeprazoleFemaleGenotypeHumansAmoxicillinAnti-Bacterial AgentsBismuthClarithromycinEsomeprazoleLevofloxacinProton Pump InhibitorsAntibiotic resistanceEradication rateFirst-line therapyHelicobacter pyloriPrecision medicine

Identifiers

PMID41278167
PMCPMC12635762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.